Pharma BD Deal Intelligence
Qurient Co., Ltd. / Synaffix B.V.
2025 · Licensing/Option · Complete
Synaffix B.V., a Lonza company, entered a licensing agreement giving South Korea-based Qurient access to its site-specific ADC platform - GlycoConnect conjugation, HydraSpace polar spacer and the exatecan-based SYNtecan linker-payload - to develop a dual-payload ADC pairing exatecan with Qurient's CDK7 inhibitor for solid tumors. Financial terms were not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Sep 25, 2025
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals